Lipoprotein(a): Testing and Treatment Updates
Understanding Lp(a) levels, risk assessment, and emerging therapeutic options for cardiovascular health.
Lipoprotein(a): An Update on Testing and Treatment
Lipoprotein(a), commonly abbreviated as Lp(a), has emerged as a significant cardiovascular risk factor that deserves greater clinical attention. Unlike other lipoproteins that are influenced by lifestyle and diet, Lp(a) levels are primarily genetically determined, making them relatively fixed throughout an individual’s lifetime. Recent advances in testing methodologies and the development of novel therapeutic approaches have transformed our understanding of how to assess and manage this important biomarker. This comprehensive update examines current guidelines for Lp(a) testing, interpretation of results, established treatment strategies, and the exciting new therapies on the horizon.
Understanding Lipoprotein(a)
Lipoprotein(a) is a particle that resembles low-density lipoprotein (LDL) but contains an additional protein called apolipoprotein(a). This unique composition makes Lp(a) particularly atherogenic, meaning it contributes to the formation of atherosclerotic plaques in blood vessels. The particle also has pro-inflammatory and pro-thrombotic properties, which means it can increase inflammation and promote blood clot formation—both risk factors for heart attacks and strokes.
The concentration of Lp(a) in the bloodstream is determined largely by genetic factors, with heritability estimates ranging from 70 to 90 percent. This means that while you cannot significantly change your Lp(a) levels through diet and exercise alone, understanding your baseline level is crucial for assessing your overall cardiovascular risk profile.
Lp(a) Testing Guidelines and Recommendations
One of the most significant developments in recent years has been the establishment of clear testing guidelines. Current guidelines support once-in-a-lifetime measurement in most individuals with increased risk of atherosclerotic cardiovascular disease. This approach recognizes that Lp(a) levels remain relatively stable throughout life, making a single measurement highly informative.
The consensus among national health organizations has grown toward recommending that everyone receive a one-time Lp(a) test. The National Lipid Association (NLA), American Heart Association, and other major cardiovascular organizations have incorporated Lp(a) testing into their clinical recommendations. This universal screening approach reflects the recognition that elevated Lp(a) is an independent risk factor that warrants identification across diverse populations.
Risk-Enhancing Cutoff Values
Interpreting Lp(a) levels requires understanding the established thresholds for risk assessment. A level greater than 50 mg/dL (or greater than 100 nmol/L) is accepted as a risk-enhancing cutoff according to the National Lipid Association scientific statement. However, it is important to recognize that risk exists on a continuum, meaning that even levels below this threshold may confer some increased risk, particularly when combined with other cardiovascular risk factors.
Individuals with elevated Lp(a) levels, particularly those exceeding these thresholds, should be considered at higher risk for premature atherosclerotic disease, myocardial infarction, and stroke. This risk is independent of LDL cholesterol levels, meaning that someone with optimal LDL control may still be at substantial risk if they have elevated Lp(a).
Current Treatment Approaches
Managing elevated Lp(a) has historically been challenging because most conventional lipid-lowering medications have shown limited effectiveness in reducing Lp(a) levels. However, recent developments have provided new options for clinicians and patients.
Traditional Lipid-Lowering Medications
Statins, the most widely prescribed class of cholesterol-lowering drugs, have shown minimal impact on Lp(a) concentrations. In fact, statins may slightly increase Lp(a) levels or leave them unchanged with therapy. This lack of effect represents a significant limitation, as statins do not address this particular cardiovascular risk factor despite their effectiveness in lowering LDL cholesterol.
Ezetimibe, another commonly used lipid-lowering medication, provides only modest Lp(a) reduction. Meta-analyses have revealed reductions of approximately 7.6 percent in Lp(a) levels with ezetimibe monotherapy, though other studies have found no significant change at all. This variable effectiveness limits its utility as a primary Lp(a)-lowering agent.
Niacin, also known as vitamin B3, has demonstrated the ability to decrease Lp(a) levels by approximately 23 percent. However, niacin is not recommended for use as an Lp(a)-lowering therapy because it lacks demonstrated mortality and morbidity benefit in patients at cardiovascular risk. The absence of clinical outcome benefits means that despite its effect on Lp(a) levels, niacin does not translate this reduction into improved cardiovascular outcomes.
PCSK9 Inhibitors: Current Standard for Lp(a) Reduction
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors represent the most effective currently available medications for reducing Lp(a) levels. These drugs, which include alirocumab and evolocumab, were originally developed and FDA-approved for LDL cholesterol reduction in patients with familial hypercholesterolemia and established cardiovascular disease.
The ODYSSEY OUTCOMES trial of alirocumab demonstrated an approximate 23 percent reduction in Lp(a) levels in treated patients. The FOURIER trial of evolocumab showed somewhat greater efficacy, with an approximate 27 percent reduction in Lp(a) concentrations. These reductions, while significant, do not approach the dramatic lowering achieved by novel therapies specifically targeting the Lp(a) pathway.
It is important to note that PCSK9 inhibitors do not have FDA approval indications specifically for individuals with high Lp(a), as they were not specifically tested in trials focused on Lp(a)-elevated populations. However, it is reasonable to use PCSK9 inhibitors among individuals who have both elevated Lp(a) and are unable to reach LDL, apolipoprotein B (ApoB), or non-HDL cholesterol goals with statins and other conventional medications.
Novel Lp(a)-Targeting Therapies
The most exciting developments in Lp(a) management come from several novel therapeutic approaches currently in clinical trials. These medications represent fundamentally different mechanisms of action compared to conventional lipid-lowering drugs, specifically targeting the genetic basis of Lp(a) production.
Small Interfering RNA (siRNA) Therapies
Small interfering RNAs are synthetic molecules designed to silence specific genes involved in Lp(a) synthesis. These therapies work by reducing the production of Lp(a) at its source—the liver, where Lp(a) particles are manufactured. Several siRNA-based therapies are currently in development:
OCEAN(a) DOSE (Olpasiran)
The OCEAN(a) DOSE trial is evaluating olpasiran (AMG 890), a siRNA that reduces Lp(a) synthesis in the liver. This phase 2 trial is testing various dosing regimens, ranging from subcutaneous injections of 10 to 225 mg administered every 12 or 24 weeks. Preliminary data suggests that this approach can achieve substantial reductions in Lp(a) levels.
SLN360
SLN360 is a double-stranded siRNA specifically targeting lipoprotein(a) messenger RNA (mRNA). In phase 2 trials, researchers are evaluating subcutaneous injections at doses ranging from 30 to 600 mg compared to placebo. This therapeutic approach aims to prevent the synthesis of Lp(a) by interfering with the genetic blueprint for its production.
Antisense Oligonucleotide (ASO) Therapies
Antisense oligonucleotides represent another innovative approach to Lp(a) reduction. These short, synthetic DNA-like molecules are designed to bind to and degrade apolipoprotein(a) messenger RNA or interfere with its translation into protein.
Pelacarsen (Lp(a) HORIZON Trial)
Pelacarsen (TQJ230) is an ASO against apolipoprotein(a) currently being evaluated in the Lp(a) HORIZON trial (Assessing the Impact of Lipoprotein [a] Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD). This phase 3 trial is testing monthly subcutaneous injections of 80 mg versus placebo and represents the first large cardiovascular outcome study specifically designed to assess whether Lp(a) lowering translates to clinical benefit. Results from this trial are projected within approximately 2 years and will be pivotal in determining the clinical relevance of Lp(a) reduction.
Additional ASO Therapies
Other antisense oligonucleotides in development include AKCEA-APO(a)-LRx (earlier iteration of pelacarsen) and LY3819469, a siRNA-based approach targeting apolipoprotein(a). These agents are in various phases of clinical testing and employ similar mechanisms to reduce Lp(a) production.
Efficacy Comparison: Injectable vs. Oral Agents
One important distinction emerging from clinical trials concerns the relative efficacy of injectable versus oral Lp(a)-lowering medications. Injectable therapies evaluated in phase 1 and phase 2 trials have demonstrated the capacity to lower Lp(a) levels by 80 to 99 percent in some cases. This extraordinary reduction potential represents a quantum leap from the modest effects achieved by conventional medications.
Oral agents in development appear to be somewhat less potent, typically achieving Lp(a) reductions in the range of 65 to 70 percent based on available phase trial data. Despite this somewhat lower efficacy compared to injectable formulations, oral medications offer the advantage of convenience and may significantly improve treatment adherence compared to parenteral administration.
Summary Table of Novel Therapies in Development
| Therapy Name | Drug (Designation) | Mechanism | Route | Trial Phase | Status |
|---|---|---|---|---|---|
| OCEAN(a) DOSE | Olpasiran (AMG 890) | siRNA reducing hepatic Lp(a) synthesis | Subcutaneous injection | Phase 2 | Ongoing |
| SLN360 | SLN360 | Double-stranded siRNA targeting Lp(a) mRNA | Subcutaneous injection | Phase 2 | Ongoing |
| ORION-11 | Inclisiran | siRNA inhibiting PCSK9 synthesis | Subcutaneous injection | Phase 3 | Ongoing |
| Lp(a) HORIZON | Pelacarsen (TQJ230) | ASO against apolipoprotein(a) | Subcutaneous injection | Phase 3 | Results expected 2025-2026 |
| AKCEA-APO(a)-LRx | Pelacarsen (ISIS 681257) | ASO against apolipoprotein(a) | Subcutaneous injection | Phase 2 | Ongoing |
| LY3819469 | LY3819469 | siRNA targeting apolipoprotein(a) | Subcutaneous injection | Phase 2 | Ongoing |
Lipoprotein Apheresis
For patients with very high Lp(a) levels and progressive cardiovascular disease despite optimal management of other risk factors, lipoprotein apheresis represents an option. This procedure involves mechanical removal of Lp(a) and other lipoproteins from the blood, similar to kidney dialysis. While effective at acutely lowering Lp(a) levels, lipoprotein apheresis is cumbersome and burdensome for patients, requiring regular sessions at specialized centers. Nevertheless, it carries an FDA indication for lowering Lp(a) and may be appropriate for carefully selected patients with extremely elevated levels and clinical evidence of progressive disease.
Emerging Risk Prediction Markers
Beyond Lp(a) levels themselves, emerging data suggest that high-sensitivity C-reactive protein (hs-CRP) levels show a strong correlation with Lp(a) for predicting cardiovascular disease risk. This finding suggests that the combination of elevated Lp(a) and markers of systemic inflammation may identify individuals at particularly high risk for adverse cardiovascular events. Future risk assessment models may incorporate both Lp(a) and inflammatory biomarkers to more precisely stratify patients into risk categories and guide treatment intensity.
Outstanding Questions and Future Directions
Despite significant progress, several critical questions remain unanswered as the field advances:
Clinical Benefit Translation
The most pressing question is whether reduced Lp(a) levels achieved through novel therapies will translate to reduced cardiovascular risk in randomized, placebo-controlled trials. While animal studies and observational data support a causal relationship between Lp(a) and atherosclerotic disease, clinical outcome trials are essential to confirm that lowering Lp(a) prevents myocardial infarctions, strokes, and cardiovascular death.
Standardization of Measurement
Another critical issue concerns which standardized assay or assays should be used globally for Lp(a) measurement. Currently, different laboratories may use different methodologies, leading to variations in reported values. Standardization would improve clinical comparability and facilitate international collaboration in research.
Risk Thresholds for Treatment
Questions persist about whether there should be specific thresholds for risk prediction and treatment decisions. Should all patients with elevated Lp(a) be treated, or only those above certain levels? Should treatment decisions differ based on the presence of other cardiovascular risk factors or established disease?
Population-Specific Treatment Strategies
The field must determine whether future Lp(a)-lowering therapy should target all persons with elevated Lp(a) levels irrespective of demographics, or whether treatment strategies should be tailored to specific populations based on age, gender, ethnicity, and other factors. Different populations may have varying baseline Lp(a) distributions and associated cardiovascular risk.
Secondary Prevention Focus
Current phase 3 trials are predominantly enrolling patients with secondary prevention indications—that is, individuals who already have evidence of cardiovascular disease. The focus on this population makes sense, as these are the patients most likely to benefit from additional risk factor modification. However, one phase 3 trial also includes high-risk primary prevention patients, which will provide important data on whether Lp(a)-lowering therapy can prevent first cardiovascular events in individuals without established disease but with markedly elevated Lp(a) levels.
Safety Considerations
To date, novel Lp(a)-lowering therapies appear to be well-tolerated and safe, with no notable adverse events reported from phase 2 and early phase 3 trials. However, clinicians and researchers are actively monitoring for potential safety concerns. Earlier observational work identified that very low Lp(a) levels—below 5 mg/dL—may be associated with certain health issues, and this possibility is being carefully monitored in ongoing clinical trials. Long-term safety data will become available as these therapies progress through development and potentially reach clinical practice.
Frequently Asked Questions
Q: Should everyone get their Lp(a) tested?
A: According to current guidelines from the National Lipid Association and American Heart Association, most people should receive a one-time Lp(a) measurement. This single test provides lifelong risk stratification, as Lp(a) levels remain relatively stable throughout life.
Q: What does an Lp(a) level above 50 mg/dL mean?
A: A level greater than 50 mg/dL (or 100 nmol/L) is considered a risk-enhancing cutoff and indicates increased cardiovascular risk, particularly for atherosclerotic disease, heart attack, and stroke. However, risk exists on a continuum, and even lower levels may carry some increased risk.
Q: Can I lower my Lp(a) through diet and exercise?
A: Unfortunately, Lp(a) levels are primarily genetically determined and cannot be significantly changed through lifestyle modifications alone. This makes pharmacologic and other medical interventions particularly important for those with elevated levels.
Q: Will statins lower my Lp(a)?
A: Statins have minimal effect on Lp(a) levels and may even slightly increase them. While statins are important for lowering LDL cholesterol, they do not address elevated Lp(a) and additional therapy may be needed.
Q: What is lipoprotein apheresis?
A: Lipoprotein apheresis is a procedure that mechanically removes Lp(a) and other lipoproteins from the blood, similar to dialysis. It is reserved for patients with very high Lp(a) levels and progressive cardiovascular disease despite optimal medical management.
Q: When will new Lp(a)-lowering medications be available?
A: Phase 3 clinical trials of novel Lp(a)-lowering therapies are currently underway, with results expected within the next 1-2 years. If these trials demonstrate clinical benefit, some therapies may receive FDA approval in 2025-2026.
Q: How much can new medications reduce Lp(a) levels?
A: Injectable novel therapies have demonstrated the ability to reduce Lp(a) levels by 80-99 percent in early trials, while oral agents typically achieve reductions of 65-70 percent. These represent dramatic improvements compared to conventional medications.
Q: Are these new therapies approved by the FDA?
A: No, novel Lp(a)-lowering therapies are still in clinical trials and do not yet have FDA approval. Final approval will depend on successful completion of phase 3 trials demonstrating clinical benefit in preventing cardiovascular events.
References
- An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Management — American College of Cardiology. 2023-09-19. https://www.acc.org/Latest-in-Cardiology/Articles/2023/09/19/10/54/An-Update-on-Lipoprotein-a
- Lipoprotein(a): What Clinicians Should Know — Harvard Medical School. 2024. https://www.youtube.com/watch?v=WgOmZsDrcEU
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic valve stenosis — National Center for Biotechnology Information (PubMed). 2022. https://pubmed.ncbi.nlm.nih.gov/36036785/
Similar Articles
Read full bio of Sneha Tete
